Cytochrome P450 (CYP) epoxygenases, CYP2C8, 2C9 and 2J2 mRNA and proteins, were expressed in prostate carcinoma (PC-3, DU-145 and LNCaP) cells. 11,12-Epoxyeicosatrienoic acid (11,12-EET) was the major arachidonic acid metabolite in these cells. Blocking EET synthesis by a selective CYP epoxygenase inhibitor (N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide [MS-PPOH]) inhibited tonic (basal) invasion and migration (motility) while exogenously added EET induced cell motility in a concentration-dependent manner. An epidermal growth factor receptor (EGFR) kinase inhibitor (AG494) or a PI3 kinase inhibitor (LY294002) inhibited cell migration and reduced 11,12-EET-induced cell migration. Importantly, synthetic EET antagonists (14,15-epoxyeicosa-5(Z)-enoic acid [14,15-EEZE], 14,15-epoxyeicosa-5(Z)-enoic acid 2-[2-(3-hydroxy-propoxy)-ethoxy]-ethyl ester [14,15-EEZE-PEG] and 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide [14,15-EEZE-mSI]) inhibited EET-induced cell invasion and migration. 11,12-EET induced cell stretching and myosin-actin microfilament formation as well as increased phosphorylation of EGFR and Akt (Ser473), while 14,15-EEZE inhibited these effects. These results suggest that EET induce and EET antagonists inhibit cell motility, possibly by putative EET receptor-mediated EGFR and PI3K/Akt pathways, and suggest that EET antagonists are potential therapeutic agents for prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398840 | PMC |
| http://dx.doi.org/10.1111/j.1349-7006.2010.01713.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolomics reveals soluble epoxide hydrolase as a therapeutic target for high-sucrose diet-mediated gut barrier dysfunction.
Proc Natl Acad Sci U S A
November 2024
Department of Anesthesia of the Second Affiliated Hospital and CNTTI of College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Article Synopsis
- A high-sucrose diet (HSD) leads to gut barrier dysfunction, including colon inflammation and tight junction damage, as observed in a mouse model over 16 weeks.
- Metabolomic analysis revealed increased soluble epoxide hydrolase (sEH) levels and decreased 5(6)-epoxyeicosatrienoic acid (5(6)-EET) in the colon, suggesting sEH as a therapeutic target for HSD-related injuries.
- Treatment with an sEH inhibitor or genetic knockout of the sEH gene reduced intestinal injuries, while 5(6)-EET showed anti-inflammatory effects and improved tight junctions, unlike its product 5,6-dihydroxyeicosatrienoic acid (5
Epoxyeicosatrienoic Acids Attenuate LPS-Induced NIH/3T3 Cell Fibrosis through the AR and PI3K/Akt Signaling Pathways.
Bull Exp Biol Med
June 2024
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Diseases, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin, China.
Article Synopsis
- * Researchers pre-treated the cells with 11,12-EET and monitored changes in protein and mRNA levels of key inflammatory markers like NF-κB and collagens I and III, finding that LPS increased these markers.
- * The results indicate that 11,12-EET reduces inflammation and fibrotic changes by enhancing the activation of AR and PI3K/Akt signaling pathways, suggesting its potential as a natural treatment for tissue fibrosis
Soluble epoxide hydrolase inhibition reverses cognitive dysfunction in a mouse model of metabolic syndrome by modulating inflammation.
Prostaglandins Other Lipid Mediat
August 2024
Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA. Electronic address:
Midlife metabolic syndrome (MetS) is associated with cognitive impairment in late life. The mechanism of delayed MetS-related cognitive dysfunction (MetSCD) is not clear, but it has been linked to systemic inflammation and chronic cerebral microangiopathy. Currently there is no treatment for late life MetSCD other than early risk factor modification.
View Article and Find Full Text PDFGPR39: An orphan receptor begging for ligands.
Drug Discov Today
February 2024
Department of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, PL 20-033 Lublin, Poland. Electronic address:
Progress in the understanding of the receptor GPR39 is held up by inconsistent pharmacological data. First, the endogenous ligand(s) remain(s) contentious. Data pointing to zinc ions (Zn) and/or eicosanoids as endogenous ligands are a matter of debate.
View Article and Find Full Text PDFTransient Receptor Potential Vanilloid (TRPV4) channel inhibition: A novel promising approach for the treatment of lung diseases.
Biomed Pharmacother
July 2023
Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam 784001, India. Electronic address:
Research on transient receptor potential vanilloid-4 (TRPV4) can provide a promising potential therapeutic target in the development of novel medicines for lung disorders. TRPV4 expresses in lung tissue and plays an important role in the maintenance of respiratory homeostatic function. TRPV4 is upregulated in life-threatening respiratory diseases like pulmonary hypertension, asthma, cystic fibrosis, and chronic obstructive pulmonary diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!